4.8 Article

Lack of Cas13a inhibition by anti-CRISPR proteins from Leptotrichia prophages

期刊

MOLECULAR CELL
卷 82, 期 11, 页码 2161-+

出版社

CELL PRESS
DOI: 10.1016/j.molcel.2022.05.002

关键词

-

资金

  1. UCSF Program for Breakthrough Biomedical Research - Sandler Foundation
  2. NIH [DP5-OD021344, R01GM127489, P01HL142494, R35GM142460]
  3. DARPA [HR0011-17-2-0043]
  4. NSF GRFP Fellowship
  5. Margaret Q. Landenberger Research Foundation
  6. Mass General Hospital Howard M. Goodman Fellowship

向作者/读者索取更多资源

This article questions the research findings of Lin et al. on CRISPR immunity and Acr proteins, highlighting inconsistencies in the study including inaccurate bioinformatics analyses and the impossibility of constructing certain bacterial strains.
CRISPR systems are prokaryotic adaptive immune systems that use RNA-guided Cas nucleases to recognize and destroy foreign genetic elements. To overcome CRISPR immunity, bacteriophages have evolved diverse families of anti-CRISPR proteins (Acrs). Recently, Lin et al. (2020) described the discovery and characterization of 7 Acr families (AcrVIA1-7) that inhibit type VI-A CRISPR systems. We detail several inconsistencies that question the results reported in the Lin et al. (2020) study. These include inaccurate bioinformatics analyses and bacterial strains that are impossible to construct. Published strains were provided by the authors, but MS2 bacteriophage plaque assays did not support the published results. We also independently tested the Acr sequences described in the original report, in E. coli and mammalian cells, but did not observe anti-Cas13a activity. Taken together, our data and analyses prompt us to question the claim that AcrVIA17 reported in Lin et al. are type VI anti-CRISPR proteins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据